Figure 5
Figure 5. NrasG12D and CBFβ-SMMHC reduce Bim-EL levels in preleukemic and leukemic cells. (A) Western blot analysis of Bim-EL expression in Lin– BM cells from control and Nras, and preleukemic cells from CM and Nras/CM mice; quantification relative to total Erk level (right panel). *P < .05. (B) Bcl2l11 transcript levels in preleukemic (Lin–) BM cells from control, Nras, CM, and Nras/CM mice relative to Actb by quantitative RT-PCR (n = 4, *P < .05). (C) Apoptosis analysis (Annexin V+/7-AAD–) of c-kit+-gated CM or Nras/CM leukemic cells (n = 4, *P < .05). (D) Western blot analysis of Bim-EL expression in CM or Nras/CM leukemic cells used in (C), and quantification relative to total Erk levels (right panel). *P < .05.

NrasG12D and CBFβ-SMMHC reduce Bim-EL levels in preleukemic and leukemic cells. (A) Western blot analysis of Bim-EL expression in Lin BM cells from control and Nras, and preleukemic cells from CM and Nras/CM mice; quantification relative to total Erk level (right panel). *P < .05. (B) Bcl2l11 transcript levels in preleukemic (Lin) BM cells from control, Nras, CM, and Nras/CM mice relative to Actb by quantitative RT-PCR (n = 4, *P < .05). (C) Apoptosis analysis (Annexin V+/7-AAD) of c-kit+-gated CM or Nras/CM leukemic cells (n = 4, *P < .05). (D) Western blot analysis of Bim-EL expression in CM or Nras/CM leukemic cells used in (C), and quantification relative to total Erk levels (right panel). *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal